Results 1 to 10 of about 21,229 (271)

Human complement regulators C4b-binding protein and C1 esterase inhibitor interact with a novel outer surface protein of Borrelia recurrentis. [PDF]

PLoS Neglected Tropical Diseases, 2010
The spirochete Borrelia recurrentis is the causal agent of louse-borne relapsing fever and is transmitted to humans by the infected body louse Pediculus humanus. We have recently demonstrated that the B.
Sonja Grosskinsky, Melanie Schott, Christiane Brenner, Sally J Cutler, Markus M Simon, Reinhard Wallich   +5 more
doaj   +8 more sources

Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis [PDF]

Frontiers in Immunology, 2023
BackgroundDysregulated complement activation, increased protein citrullination, and production of autoantibodies against citrullinated proteins are hallmarks of rheumatoid arthritis (RA).
Myriam Martin, Sara C. Nilsson, David Eikrem, Karin Fromell, Carsten Scavenius, Leonie M. Vogt, Ewa Bielecka, Jan Potempa, Jan Potempa, Jan J. Enghild, Bo Nilsson, Kristina N. Ekdahl, Kristina N. Ekdahl, Meliha C. Kapetanovic, Anna M. Blom   +14 more
doaj   +2 more sources

The role of C1 inhibitor and complement as acute phase reactants: are we missing the diagnosis of hereditary angioedema?

Allergy, Asthma & Clinical Immunology, 2021
Background C1 inhibitor (C1-INH) and complement 4 (C4) have historically been referred to as positive acute phase reactants, however this has never been evaluated in hereditary angioedema (HAE) patients.
Peter Stepaniuk, Ana-Maria Bosonea, Persia Pourshahnazari, Adrienne Roos, Amin Kanani   +4 more
doaj   +2 more sources

Molecular Basis for Bordetella pertussis Interference with Complement, Coagulation, Fibrinolytic, and Contact Activation Systems: the Cryo-EM Structure of the Vag8-C1 Inhibitor Complex

mBio, 2021
Complement, contact activation, coagulation, and fibrinolysis are serum protein cascades that need strict regulation to maintain human health. Serum glycoprotein, a C1 inhibitor (C1-INH), is a key regulator (inhibitor) of serine proteases of all the ...
Arun Dhillon, Justin C. Deme, Emily Furlong, Dorina Roem, Ilse Jongerius, Steven Johnson, Susan M. Lea   +6 more
doaj   +2 more sources

Overexpression of key complement regulators in glioblastoma. [PDF]

PLoS ONE
BackgroundGlioblastoma (GBM) is the most prevalent and malignant primary brain tumor in adults. While immune evasion is a well-recognized driver of GBM progression and a major obstacle for efficient immunotherapy, the role of the complement system ...
Linnea Blomberg, Leonora Raba, Johan Bengzon, Kurt Osther, Henrietta Nittby Redebrandt   +4 more
doaj   +2 more sources

Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model. [PDF]

PLoS ONE, 2014
Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system in which binding of anti-aquaporin-4 (AQP4) autoantibodies (NMO-IgG) to astrocytes causes complement-dependent cytotoxicity (CDC) and inflammation resulting ...
Lukmanee Tradtrantip, Nithi Asavapanumas, Puay-Wah Phuan, A S Verkman   +3 more
doaj   +2 more sources

SARS-CoV-2 nucleocapsid protein forms complexes with soluble complement regulatory proteins that can bind to the virion [PDF]

Scientific Reports
The SARS-CoV-2 nucleocapsid protein has been detected in the plasma of COVID-19 patients, and its levels in the plasma correlate with the severity of the disease. It is also an immunomodulatory protein, triggering the release of proinflammatory cytokines.
Jakub Víglaský, Katarína Bhide, Lea Talpasova, Ľubica Fialová, Mangesh Bhide   +4 more
doaj   +2 more sources

Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor

World Allergy Organization Journal, 2022
Background: Hereditary angioedema (HAE) is often caused by low serum levels or functional deficiency in C1 inhibitor (C1-INH); however, in some cases, C1-INH serum level and function are measured as normal (HAE-nl-C1INH).
Douglas H. Jones, MD, Priya Bansal, MD, Jonathan A. Bernstein, MD, Shahnaz Fatteh, MD, Joseph Harper, PharmD, F. Ida Hsu, MD, Maeve O’Connor, MD, Nami Park, PharmD, Daniel Suez, MD   +8 more
doaj   +1 more source

Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry

World Allergy Organization Journal, 2021
Background: Hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling attacks. A European treatment registry was established to review the adverse event profile and efficacy of recombinant ...
Anna Valerieva, Maria T. Staevska, Vesna Grivcheva-Panovska, Milos Jesenak, Kinga Viktória Kőhalmi, Katarina Hrubiskova, Andrea Zanichelli, Luca Bellizzi, Anurag Relan, Roman Hakl, Henriette Farkas   +10 more
doaj   +1 more source

C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?

Clinical Immunology Communications, 2022
From asymptomatic to severe, SARS-CoV-2, causative agent of COVID-19, elicits varying disease severities. Moreover, understanding innate and adaptive immune responses to SARS-CoV-2 is imperative since variants such as Omicron negatively impact adaptive ...
Melissa A. Hausburg, Jason S. Williams, Kaysie L. Banton, Charles W. Mains, Michael Roshon, David Bar-Or   +5 more
doaj   +1 more source